Leukemia Clinical Trial
Official title:
A Phase II Study of Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia
Ph+ leukemias (i.e.Chronic Myelogenous Leukemia (CML) and (Ph+) Acute Lymphoblastic Leukemia
are malignant clonal disorder of the hemopoietic stem cell due to reciprocal translocation
of genetic material between chromosome 9 and 22 giving rise to the translocation t(9;22)
(q2.2; q2.1). The translocation causes the formation of a new hybrid gene (bcr-abl) that
codes for a 185 kb or 210 kb cytoplasmic protein (P185 and P210 respectively) that by
autophosphorylation activates a number of signaling pathways involved in cell proliferation,
maturation, apoptosis and adhesion, leading to the malignant cell transformation1-3. The
course of the disease goes on through a chronic phase (CP), usually lasting some years, that
is characterized by a massive myeloid hyperplasia with hyperleukocytosis and splenomegaly.
The CP is almost always followed by an accelerated or blastic phase (ABP) where the leukemic
process acquires the characteristics of acute leukemia. The ABP usually lasts some months
and terminates with the death of the patient3.
The frequency of CML in western countries ranges between 10 and 15 per million persons (age
- standardized). It is rare in children. The median age is 55 years.
Current treatment of CML includes conventional chemotherapy, allogeneic bone marrow
transplantation (allo BMT), alpha-interferon (alpha-IFN)and imatinib.
Status | Completed |
Enrollment | 3 |
Est. completion date | February 2008 |
Est. primary completion date | February 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria for chronic phase patients : 1. Age >/=18 years 2. Ph positive 3. Absence of a CHR after 3 months on imatinib 4. Loss of a previously obtained CHR on imatinib alone 5. Absence of a CCgR within 12 months on imatinib alone 6. Loss of a previously obtained CCgR on imatinib alone 7. Written informed consent Exclusion Criteria for chronic phase patients : 1. Age <18 2. Performance status (ECOG/WHO) > 2 (see Appendix 2) 3. Inability to provide written informed consent 4. Pregnancy 5. Accelerated or blastic phase 6. Formal refusal of any recommendation of a safe contraception 7. Alcohol or drug addiction 8. Altered hepatic or renal function as defined by AST/ALT or bilirubin > 3 times upper normal limits (UNL) 9. Serum creatinine > 265 umol/l or >3.0 mg/dl 10. Any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioural problems. Inclusion criteria for accelerated and blastic phase or acute lymphoblastic leukemia Ph+ patients: 1. Age >/=18 years 2. Ph positive 3. Loss of a previous hematological response to imatinib alone, with further progression to ABP (see section 14 for definitions) 4. Performance status (ECOG/WHO) 5. Written informed consent Exclusion criteria for accelerated and blastic phase or acute lymphoblastic leukemia Ph+ patients: 1. Age <18 2. Performance status (ECOG/WHO) > 2 (see Appendix 2) 3. Inability to provide written informed consent 4. Pregnancy 5. Chronic Phase disease 6. Formal refusal of any recommendation of a safe contraception 7. Alcohol or drug addiction 8. Altered hepatic or renal function as defined by AST/ALT or bilirubin > 3 times upper normal limits (UNL) 9. Serum creatinine > 265 umol/l or >3.0 mg/dl 10. Any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioural problems. |
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | Policlinico "S.Orsola-Malpighi"-Istituto di Ematologia "L e A Seragnoli" | Bologna |
Lead Sponsor | Collaborator |
---|---|
University of Bologna |
Italy,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |